Pemvidutide for MASH and Liver Disease: What the Research Shows

Pemvidutide was developed by Altimmune, a clinical-stage biopharmaceutical company. The molecule is a balanced dual agonist, meaning it activates both the GLP-1 receptor (the same target as semaglutide and tirzepatide) and the glucagon receptor with roughly equal potency. This dual mechanism was intentional. GLP-1 agonism provides the appetite suppression and metabolic improvements people know from weight-loss drugs. Glucagon receptor activation does something different: it increases fat oxidation in the liver and promotes energy expenditure. The drug moved through Phase 2 trials for obesity before Altimmune pivoted its primary focus to MASH. The rationale was that the glucagon component, which can actually work against pure weight loss by raising blood sugar, becomes an asset when the goal is clearing fat from liver tissue. The FDA granted breakthrough therapy designation based on Phase 2 MASH data showing that a majority of patients achieved at least a one-point improvement in fibrosis stage without worsening of MASH.

MASH develops when fat accumulates in liver cells, triggering inflammation and eventually fibrosis (scarring). The progression goes: simple fatty liver (MASLD) to MASH to fibrosis to cirrhosis. Pemvidutide interrupts this cascade through two pathways simultaneously. The GLP-1 side reduces appetite and improves insulin sensitivity, which lowers the amount of fat being delivered to the liver in the first place. The glucagon side directly stimulates hepatic fat oxidation, meaning the liver burns through the fat already stored in its cells. Glucagon also promotes autophagy, the cellular cleanup process that removes damaged organelles and protein aggregates from hepatocytes. This combination matters because single-mechanism drugs often hit a ceiling. GLP-1 agonists alone reduce liver fat modestly, but they do not directly address the inflammation and fibrosis that make MASH dangerous. Glucagon alone can worsen glycemic control. Together, they produce effects that neither achieves independently.

In the Phase 2 IMPACT trial, pemvidutide at the 2.4 mg dose produced the following results over 48 weeks:

• Mean body weight reduction of approximately 15%
• MASH resolution without worsening fibrosis in a significant proportion of patients
• At least one-point improvement in fibrosis stage in a majority of responders
• Reductions in liver enzymes (ALT, AST) indicating less hepatocyte damage
• Decreased liver fat content measured by MRI-PDFF

The weight loss is notable but secondary to the liver outcomes. For context, the MASH resolution rates compared favorably with resmetirom (the first FDA-approved MASH drug), though head-to-head trials have not been conducted.

Most participants in clinical trials reported side effects similar to other GLP-1 agonists: nausea during the first few weeks, decreased appetite, and occasional gastrointestinal discomfort. A user on r/MASHDisease described the trial experience as “the nausea was rough for about three weeks, then it faded. My liver numbers started improving by month two.“ Another participant noted that the appetite suppression felt “less intense than semaglutide, maybe because the glucagon component keeps energy up a bit.“ The typical titration schedule starts at a low dose and increases gradually over 8 to 12 weeks. Most side effects occur during dose escalation and stabilize once the maintenance dose is reached.

• Reduction in liver fat content, confirmed by imaging or blood markers
• Lower ALT and AST levels on routine bloodwork
• Weight loss, though typically less dramatic than pure GLP-1 agonists like tirzepatide
• Improved insulin sensitivity and fasting glucose
• Reduced liver stiffness on elastography (a measure of fibrosis)
• Decreased markers of systemic inflammation (CRP, ferritin)

• MOTS-c: Targets mitochondrial function and may complement pemvidutide's fat-oxidation pathway by improving cellular energy metabolism in hepatocytes.
• BPC-157: Has demonstrated hepatoprotective effects in preclinical models, including reducing oxidative stress in liver tissue. Some clinicians combine it with metabolic peptides for gut-liver axis support.
• GHK-Cu: Copper peptides support tissue repair and have shown anti-fibrotic properties in skin. Research into their effects on hepatic fibrosis is early but promising.
• Thymosin alpha-1: For patients with MASH complicated by immune dysregulation, thymosin alpha-1's immunomodulatory effects may help reduce the inflammatory component of liver disease.